PDF printable version of Childhood Pneumococcal Immunisation Provider GuidelinesProgram Providing a Supplementary Dose of the 13-valent pneumococcal vaccine (13vPCV) - Updated 5 September 2011 (PDF 151 KB)
Why is a supplementary dose of 13vPCV being made available?From 1 October 2011 until 30 September 2012, the Australian Government will provide a free supplementary dose of 13vPCV to eligible children who have completed their primary pneumococcal vaccination course with 7vPCV. This has been introduced so they can benefit from protection from the additional six serotypes covered by 13vPCV. This includes serotype 19A which is becoming increasingly predominant.
Who is eligible to receive a free supplementary dose of 13vPCV?Under the National Immunisation Program, only children aged between 12 months and 35 months who have completed a primary pneumococcal vaccination course with 7vPCV are eligible to receive a free supplementary dose of 13vPCV. A single dose for these children is expected to provide the same benefits as primary series vaccination with 13vPCV both in terms of direct effects and accelerating herd effects.
The Commonwealth’s Chief Medical Officer will be writing to parents/guardians of eligible children about the availability of the free dose.
In the Northern Territory, the Territory Government will provide a free dose of 13vPCV at 18 months for children who have previously received a primary pneumococcal course of 10vPCV or a mixed primary pneumococcal course with 10vPCV and 7vPCV.
Parents/carers of children who are not eligible to receive a free dose of 13vPCV are able to access the vaccine on prescription. 13vPCV is only registered for children up to five years of age.
Aboriginal and Torres Strait Islander children between the ages of 18 to 24 months in Queensland, South Australia and Western Australia do not require a booster dose of 23-valent pneumococcal polysaccharide vaccine (23vPPV, Pneumovax 23) if they receive the supplementary dose of 13vPCV between the ages of 12 months and 35 months. If these children have already received 23vPPV, they should also receive the supplementary dose of 13vPCV as it provides protection against the additional serotypes, including 6A which is not in 23vPPV. The supplementary dose should be given at least 8 weeks after 23vPPV.
Children with underlying medical conditions1 who have received a booster dose of 7vPCV at 12 months of age are also eligible to receive a supplementary dose of 13vPCV. This should be given at least 2 months after the fourth dose of 7vPCV was given. Children with underlying medical conditions should also receive a dose of 23vPPV (Pneumovax 23) between 4 and 5 years of age.
BackgroundFrom 1 July 2011, all states and the Australian Capital Territory replaced a 7‑valent pneumococcal conjugate vaccine (7vPCV, Prevenar®) with a 13-valent pneumococcal conjugate vaccine (13vPCV, Prevenar 13®). From 1 October 2011, the Northern Territory will replace the 10‑valent pneumococcal conjugate vaccine (10vPCV, Synflorix®) with a 13-valent pneumococcal conjugate vaccine (13vPCV, Prevenar 13®).
Can pneumococcal vaccine be given at the same time as other vaccines?There may be a small increased risk of fever / febrile convulsions with the co-administration of trivalent influenza and pneumococcal conjugate vaccines in children 12–35 months of age. Australian Technical Advisory Group on Immunisation advice is that these vaccines may be given together and that providers discuss this risk with parents prior to administration of 13vPCV. If there are strong parental concerns, these vaccines may be administered separately using an interval of at least three days between each vaccine.
How can I get more information?Go to the Immunise Australia Program website, or contact your local state or territory health department.
1See Australian Immunisation Handbook, 9th Edition, 2008